Adipotide (FTPP) Peptide

Adipotide (FTPP) is a chimeric peptide that selectively destroys blood vessels feeding white adipose tissue via prohibitin binding and mitochondrial membrane disruption.

Adipotide, also referred to as fat-targeted proapoptotic peptide (FTPP), is a bifunctional chimeric peptidomimetic designed to exploit a tissue-specific vascular address system. It consists of two functionally distinct domains joined by a glycine-glycine (GG) linker: a homing peptide sequence CKGGRAKDC and a proapoptotic effector sequence D(KLAKLAK)₂. Each domain contributes to a sequential mechanism of vascular targeting followed by localized endothelial cell death.

Prohibitin-Mediated Vascular Homing

The CKGGRAKDC motif was identified through in vivo phage display biopanning in mice and shown to bind selectively to prohibitin-1 (PHB1), a membrane-associated chaperone protein that is differentially expressed on the luminal surface of endothelial cells lining white adipose tissue (WAT) vasculature. Although prohibitin is widely expressed intracellularly in mitochondria, its cell-surface localization on WAT endothelium provides a vascular zip code that the homing peptide recognizes with relative specificity, sparing the vasculature of most other organs in preclinical models.¹

D(KLAKLAK)₂ Proapoptotic Domain

Once the chimeric peptide docks onto the adipose endothelial surface, the D(KLAKLAK)₂ sequence — an amphipathic, cationic α-helical peptide composed of D-amino acids — is internalized and translocates to mitochondrial membranes. There it disrupts the mitochondrial outer membrane potential, leading to cytochrome c release, caspase activation, and rapid apoptotic cell death of the targeted endothelium. The use of D-amino acids confers resistance to proteolytic degradation while preserving membrane-disrupting activity, since this function depends on amphipathic helix geometry rather than chiral receptor recognition.²

Downstream Vascular and Adipose Effects

Selective apoptosis of WAT endothelial cells has been associated, in preclinical models, with capillary regression in adipose depots and secondary loss of adipocyte mass, presumably through diminished blood supply and trophic support. Imaging and histological analyses in obese mice and non-human primates have reported reductions in body fat following systemic administration of adipotide, without comparable depletion of lean tissue or brown adipose vasculature in the original studies.^1,2

Selectivity Considerations

Because prohibitin is also expressed on other vascular beds and intracellularly across many tissues, vascular targeting selectivity is not absolute. Preclinical toxicology studies have flagged renal proximal tubule effects in some species, suggesting that the homing peptide may also accumulate in the kidney. These observations have shaped subsequent research into dose-response relationships and structural analogs aimed at refining tissue selectivity.

Mechanistically, adipotide therefore represents a model system for studying ligand-directed vascular pharmacodelivery: combining a peptide address with a payload effector. It is widely used in research as a tool compound to interrogate adipose vascular biology, prohibitin function, and endothelial apoptosis pathways rather than as a generic anti-obesity agent.

Adipotide (FTPP, Fat-Targeted Proapoptotic Peptide) is a chimeric peptidomimetic combining a cyclic disulfide-constrained homing motif with a D-amino-acid proapoptotic helix. The construct's biophysical characteristics reflect this dual-domain architecture: a hydrophilic, cysteine-bridged adipose-homing loop linked through a glycine-glycine spacer to a strongly cationic amphipathic helix composed of D-enantiomer residues. Researchers should note that the D-amino acid composition of the KLAKLAK domain confers significant protease resistance compared with all-L analogs, an important determinant of in vivo half-life.

The cationic amphipathic character of the D(KLAKLAK)2 domain is essential for its mitochondrial membrane-disrupting activity once internalized via prohibitin-mediated endocytosis. This domain is inactive in the extracellular environment because intact eukaryotic plasma membranes exclude it; only after receptor-targeted uptake does it gain access to the negatively charged inner mitochondrial membrane, where it induces membrane permeabilization and subsequent apoptosis. Researchers handling Adipotide should be aware that the disulfide bridge in the homing motif is critical for prohibitin binding affinity, and reducing conditions during reconstitution or storage can compromise targeting specificity.

Adipotide (FTPP) is a chimeric peptidomimetic that requires careful reconstitution to preserve both its disulfide-constrained homing motif and the integrity of its cationic amphipathic D-amino acid helix. The following protocol reflects standard preclinical handling practice and should be adapted by qualified research personnel to specific experimental requirements. Adipotide is for in vitro and preclinical animal research use only and is not intended for human administration.

Step-by-Step Reconstitution Protocol:

1. Equilibrate the vial to room temperature for 20-30 minutes before opening to minimize condensation on the lyophilized cake, which can promote disulfide scrambling and hydrolytic degradation.
2. Centrifuge briefly (1,000-2,000 × g for 30 seconds) to ensure all lyophilized material is at the bottom of the vial.
3. Select a diluent: Sterile water for injection or bacteriostatic water (0.9% benzyl alcohol) are the most common solvents for in vivo research. For cell-culture assays, sterile PBS (pH 7.4) is acceptable. Avoid alkaline buffers (pH > 8), which accelerate disulfide exchange.
4. Calculate target concentration: A typical working stock is 5 mg/mL. For a 5 mg vial, add 1.0 mL of diluent; for a 10 mg vial, add 2.0 mL.
5. Add diluent slowly down the side of the vial, directing the stream onto the glass wall rather than directly onto the powder cake to minimize foaming.
6. Gently swirl or invert the vial 10-15 times. Do not vortex or shake vigorously, as shear forces can denature the amphipathic helix and induce aggregation of the cationic peptide.
7. Allow 5-10 minutes for complete dissolution. The solution should appear clear and colorless. Any cloudiness or precipitate indicates compromised material.
8. Aliquot the reconstituted stock into low-protein-binding tubes in single-use volumes to minimize freeze-thaw cycles.

Compound-Specific Handling Notes:

• Disulfide integrity: The intramolecular Cys1-Cys9 disulfide bond in the CKGGRAKDC homing motif is essential for prohibitin-1 binding. Avoid reducing agents (DTT, β-mercaptoethanol, TCEP) in any buffer that will come into contact with the active peptide.
• Surface adsorption: Cationic peptides like Adipotide can adsorb to glass and standard polypropylene at low concentrations. Use low-protein-binding plasticware (e.g., Eppendorf LoBind) for dilute working solutions below 100 μg/mL.
• Endotoxin awareness: For in vivo animal work, ensure all reconstitution materials are pyrogen-free, as endotoxin contamination can confound interpretation of weight-loss and vascular endpoints.
• Dosing dilutions: Prepare dosing solutions fresh each day from the frozen stock; do not refreeze diluted working solutions.

All work should be conducted under appropriate institutional biosafety and animal-care oversight, with personal protective equipment including gloves, lab coat, and eye protection.